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Abstract
Background: Thiazide diuretics are cost-effective for the treatment of mild to moderate hypertension, but
physicians often opt for more expensive treatment options such as angiotensin II receptor blockers or angiotensin
converting enzyme inhibitors. With escalating health care costs, there is a need to elucidate the factors influencing
physicians’ treatment choices for this highly prevalent chronic condition. The purpose of this study was to describe
the characteristics of physicians’ decision-making process regarding hypertension treatment choices.
Methods: A comparative qualitative study was conducted in 2009 in the Canadian province of Quebec. Overall, 29
primary care physicians–who are also participating in an electronic health record research program–participated in
a semi-structured interview about their prescribing decisions. Physicians were categorized into two groups based
on their patterns of prescribing antihypertensive drugs: physicians who predominantly prescribe diuretics, and
physicians who predominantly prescribe drug classes other than diuretics. Cases of hypertension that were newly
started on antihypertensive therapy were purposely selected from each physician’s electronic health record
database. Chart stimulated recall interview, a technique utilizing patient charts to probe recall and provide context
to physician decision-making during clinical encounters, was used to elucidate reasons for treatment choices.
Interview transcripts were synthesized using content analysis techniques, and factors influencing physicians’
decision making were inductively generated from the data.
Results: We identified three themes that differentiated physicians who predominantly prescribe diuretics from
those who predominantly prescribe other drug classes for the initial treatment of mild to moderate hypertension:
a) perceptions about the efficacy of diuretics, b) preferred approach to hypertension management and, c)
perceptions about hypertension guidelines. Specifically, physicians had differences in beliefs about the efficacy,
safety and tolerability of diuretics, the most effective approach for managing mild to moderate hypertension, and
in aggressiveness to achieve treatment targets. Marketing strategies employed by the pharmaceutical industry and
practice experience appear to contribute to these differences in management approach.
Conclusions: Physicians preferring more expensive treatment options appear to have several misperceptions about
the efficacy, safety and tolerability of diuretics. Efforts to increase physicians’ prescribing of diuretics may need to
be directed at overcoming these misperceptions.
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Hypertension is one of the most prevalent chronic con-
ditions worldwide. The age–and sex-adjusted prevalence
of hypertension is estimated to be 28% among North
American countries, whereas it is estimated to be as
high as 44% in European countries [1-3]. Hypertension
has been identified as the most important modifiable
risk factor for cardiovascular morbidity and mortality
[4,5], and pharmacotherapy is an important aspect of
hypertension management [6]. Numerous pharmacologi-
cal agents exist for the treatment of hypertension,
including thiazide diuretics, angiotensin converting
enzyme inhibitors (ACEIs), angiotensin II receptor
blockers (ARBs), calcium channel blockers (CCBs), and
beta-blockers (BBs) [7-9], and these agents vary consid-
erably in cost [7].
While there is evidence that specific pharmacological
agents have benefits for patients with particular co-mor-
bidities (e.g., diabetes or nephropathy) [8], for the
majority of patients with mild to moderate hypertension,
the major randomized control trials [10,11], meta-ana-
lyses and systematic reviews [12-16] have provided evi-
dence that initial monotherapy with a thiazide diuretic
is as equally effective as the other therapeutic agents in
preventing cardiovascular mortality and morbidity. For
this reason, and because they are the least costly agents
[7], many evidence-based guidelines have recommended
that low doses of diuretics should be considered as the
first-line treatment of mild to moderate uncomplicated
hypertension [9,17,18].
Despite this evidence, studies demonstrate that many
physicians favour more expensive alternatives such as
angiotensin II receptor blockers (ARBs) or angiotensin
converting enzyme inhibitors (ACEIs) for the initial
treatment of patients with mild to moderate uncompli-
cated hypertension [6,19]. This observation is striking
given the escalation of health care expenditures, and
given that hypertension is one of the most costly condi-
tions treated by primary care physicians [20]. It is also
remarkable given that access to affordable medications
has been identified as an important determinant of
adherence to and persistence with hypertension treat-
ment [19,21,22], and thus of improved health outcomes.
To improve the cost-effectiveness of hypertension man-
agement and patients’ compliance with hypertension
treatment, there is a need to have a better understand-
ing of the factors that influence physicians’ decision
making when selecting an antihypertensive treatment.
The purpose of this study was to describe the character-




The study was conducted in Quebec, Canada, a province
with 8.5 million residents and 16, 000 physicians. The
provincial insurance agency (RAMQ) provides health
insurance for all provincial residents, and pays all physi-
cians and community pharmacists on a fee-for-service
basis. Beneficiary, medical billing and pharmacy claims
data can be used to create longitudinal health histories
for each patient. This data has been validated [23] and
is frequently used for health services and epidemiologi-
cal research [24,25].
Since 2003, the Medical Office of the 21st Century
(MOXXI) [26,27], an experimental community-based
clinical information system (CIS), links these databases
and integrates this information into an electronic health
record system to support clinical decision-making. This
electronic health record provides physicians with: (1) a
daily updated drug profile for each of their patients that
reflects current and past medications as well as drug
costs; (2) a list of health problems that includes diag-
noses recorded on billings by all physicians who treat a
given patient; (3) dates and reasons for emergency room
visits and hospitalizations. In addition, the MOXXI sys-
tem has additional features to support clinical manage-
ment and decision making, including an electronic
prescribing system that records treatment indications
and adds them to the problem list as well as reasons for
drug discontinuation orders (documentation of adverse
drug events), information on past treatment, drug/
allergy and disease alerts, and various experimental deci-
sion support systems. Taking advantage of this CIS, we
sought to describe the characteristics of physicians’ deci-
sion-making process regarding hypertension treatment
choices.
Study design & participants
A comparative qualitative study, using chart stimulated
recall interview [28-30], was conducted to elucidate dif-
ferences in clinical policies that would lead physicians to
prescribe cost-effective first line treatment (thiazide
diuretics) rather than alternate therapeutic classes or
multiple therapies to patients with mild to moderate
uncomplicated hypertension within their practice. Chart
stimulated recall interview is a technique by which a phy-
sician uses documentation of actual patient encounters
to stimulate recall of his or her own decision-making
processes while an evaluator probes the reasoning behind
the decision-making [28,30]. Chart stimulated recall
interviews help address the well described discrepancy
between physicians’ perceived and actual behaviors, as
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chart review [28]. Several studies support the validity of
this method for assessing the cognitive decision-making
processes that influence performance [28-30].
Overall, 29 of the 80 primary care physicians using
the MOXXI clinical information system (CIS) agreed
to participate in a chart stimulated recall analysis of
their prescribing decisions. The major reasons for
declining to participate in the study were lack of time
or interest. For the participating physicians, we used
the MOXXI CIS system to purposely sample patients
from each physician’s practice who represented varia-
t i o n si nag i v e np h y s i c i a n ’s approach to hypertension
management. We restricted the analyses to patients
who were newly started on therapy (incident patients)
so that we would analyse only those patients for whom
the study physician was making the initial therapeutic
decision. This restriction was necessary because pri-
mary care physicians often renew medications started
by other physicians and their prescribing practices in
these instances do not necessarily reflect their own
clinical decisions [31]. We identified incident hyperten-
sion patients as those who had a diagnosis of hyper-
tension by the study physician and no prior
prescription for an antihypertensive drug. We first
stratified all incident patients started on therapy within
the last year into two groups: (1) started on diuretics
alone or (2) started on calcium channel blockers
(CCBs), angiotensin II receptor blockers (ARBs), angio-
tensin converting enzyme inhibitors (ACEIs), beta-
blockers (BBs) either alone or in combination with
other drugs. We then stratified physicians into two
groups: 1) prescribed diuretics as first-line therapy for
most patients, or 2) never or rarely prescribed diuretics
as first-line therapy. For each physician, we randomly
sampled two incident patients for the chart stimulated
recall interview; one on which the physician prescribed
diuretics as first line treatment and a second where
alternate therapy was selected. For physicians who
never or rarely prescribed diuretics, we randomly
selected two patients who were started on alternate
treatment.
Chart stimulated recall
A semi-structured interview guide was developed from
the literature to elucidate the factors that guided physi-
cians’ treatment choices, based on the patient character-
istics to be considered in hypertension management, as
well as environmental characteristics that influence phy-
sicians’ prescribing and adoption of new drugs [32-34].
The chart-stimulated recall interview guide was designed
to start with four open-ended questions: (1) the ratio-
nale for their choice of therapy, (2) whether this was an
approach used with similar patients and why, (3) how
long they used this approach to treatment, and the fac-
tors that led them to adopt this strategy, and 4) the rea-
sons for differences between the approach to the two
patients (when relevant). In addition, the interview guide
included a series of open-ended questions about the
physician’s general approach to hypertension, including:
the length of time they have been treating patients for
hypertension, whether they have changed their approach
to hypertension treatment and why, the circumstances
in which they would add a drug vs. increase the dose
for existing therapy to control hypertension, the circum-
stances in which they would select diuretics over other
classes of therapy, the sources of information used to
keep informed about hypertension treatment, and the
effect of the results of the ALLHAT [11] trial on their
hypertension treatment choices.
Prior to each interview, the physician was informed as
to which patients had been randomly selected from his/
her practice so that the charts could be retrieved for
consultation during the interview process. A trained
interviewer was provided with the names of the two
selected patients and the date and type of antihyperten-
sive therapy that had been initially prescribed. All inter-
views were tape-recorded with the permission of the
physicians and transcribed verbatim. The study was
approved by the institutional ethics review board at
McGill University. Informed consent was obtained prior
to any chart stimulated recall interview.
Analysis
Descriptive statistics were used to summarize physicians’
characteristics (e.g., sex, years of practice experience)
and those of their practice (i.e., mean annual patient
volume, mean number of incident patients treated for
uncomplicated hypertension, and mean number of
patients with uncomplicated hypertension who were
started on diuretics). To describe the characteristics of
physicians’ decision-making process regarding hyperten-
sion treatment choices, a systematic process of inductive
data analysis involving content analysis was used
[35-37]. Specifically, through iterative readings of the
interview transcripts, a listo fc o d e sw a si n d u c t i v e l y
developed to characterize sentences, paragraphs or sec-
tions of the transcripts. Codes were then compared and
contrasted, and similar codes were grouped into cate-
gories to delineate emerging themes that corresponded
to factors characterizing physicians’ decision-making
process regarding hypertension treatment choices. Quo-
tations representing these themes were extracted from
the interview transcripts, and identifying information
was masked to protect the confidentiality of the infor-
mants and that of their patients. The analyses were per-
formed independently by two of the authors (CMR and
JM) who then met to discuss their codification and
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resolved through discussion among the research team.
Results
On average, physicians who predominantly prescribe
diuretics had fewer years of practice experience, saw
fewer patients, and treated fewer new patients with
uncomplicated hypertension (Table 1). On average,
these physicians started four times as many patients
with uncomplicated hypertension on a diuretic com-
pared to physicians who tended to use other classes of
treatment (28.2% vs. 7.2%) (Table 1). Three themes
emerged from the analysis of the interview data. These
themes differentiated physicians who predominantly pre-
scribe diuretics as a first-line treatment of mild to mod-
erate uncomplicated hypertension from those who
predominantly prescribe drug classes other than diure-
tics: a) perception about the efficacy of diuretics, b) pre-
ferred approach to hypertension management, and c)
perceptions about hypertension guidelines.
Perceptions about the efficacy of diuretics
Physicians from both groups agreed that for patients
with complicated hypertension (i.e., patients with dia-
betes, renal or cardiac disease) they would initiate an
antihypertensive therapy with an angiotensin converting
enzyme inhibitor (ACEI) or an angiotensin II receptor
blocker (ARB) in order to provide these patients with
the required cardiovascular or renal protection. Physi-
cians also agreed that the target blood pressures should
be < 130/80 mmHg in patients with diabetes or chronic
kidney disease, and < 140/80 mmHg in patients with
uncomplicated hypertension. However, physicians dif-
fered in their perceptions of the efficacy of diuretics for
managing patients with mild to moderate uncomplicated
hypertension. Indeed, physicians who predominantly
prescribe diuretics described these drugs as being effec-
tive and as having few side effects:
“I find that diuretics are safe, effective, and inexpen-
sive. I don’t think there are any better drugs. I use
them often.” (MD 18)
“Unless there is a compelling indication, I usually
start with that [i.e. diuretics].E v e nb e f o r et h eA L L -
HAT study, I was kind of doing that because I didn’t
think there was any benefit to one over the other, but
with ALLHAT, it made it easier.” (MD 19)
“For me a diuretic is the first line, unless there’sa n
indication to use a different drug, such as with a
diabetic patient, or a contra-indication to use diure-
t i c s ,s u c ha si nap a t i e n tw i t hah i s t o r yo fg o u t .”
(MD 28)
However, among physicians who predominantly pre-
scribe drug classes other than diuretics, the perception
of diuretics was the opposite:
“We always said that diuretics are among the drugs
that can cause more side effects. Then, when ACE
inhibitors and angiotensin II receptor blockers and
those things came along, we had far fewer side effects.
And most of the time, you can’t control blood pres-
sure with a diuretic alone; diuretics for us, at least
for me and for lots of people here, are mainly for sec-
ond line. Even for mild hypertension, we rarely start
with a diuretic.” (MD 8)
“Diuretics are among those drugs that have a thresh-
old effect. Beyond 25 mg per day, you start having all
sorts of adverse effects.” (MD 2)
“In comparison to the other classes, I am very scepti-
cal [about the equivalent efficacy of diuretics]; [...] I
find that some classes are more effective. Some drugs
are more effective than others.” (MD 12)
“It r yt ou s et h e m[i.e., diuretics], but they have side
effects, including hyponatremia in older people. They
also offer less protection against future morbidity [...]
with more side effects.” (MD 14)
Table 1 Characteristics of the 29 physicians who participated in the study
Characteristics Physicians who predominantly
prescribe diuretics (n = 13)
Physicians who predominantly prescribe
other drug classes (n = 16)
Sex N (%) N (%)
Female 6 (46.1) 8 (50.0)
Male 7 (53.9) 8 (50.0)
Mean ± SD Mean ± SD
Years of practice experience 21.9 ± 13.3 24.0 ± 5.4
Number of patients seen in 2009 1, 000.5 ± 544.3 1, 420.2 ± 743.6
Number of incident patients with uncomplicated
hypertension (2009)
71.8 ± 62.9 99.3 ± 75.1
Mean proportion (%) of incident patients with uncomplicated
hypertension started on diuretics (2009)
28.2% ± 11.3% 7.2% ± 4.3%
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other than diuretics placed a great deal of emphasis on
the frequency and the number of side effects associated
with using diuretics, including electrolytic disorders (e.
g., hypokalemia, hyponatremia), renal failure due to
dehydration, increased urinary frequency, and ortho-
static hypotension. Some of these physicians also noted
that diuretics alone may not be as effective as other
drug classes in reaching patients’ blood pressure targets.
These physicians also believed that diuretics do not pro-
vide patients with the same renal and cardiovascular
protection as the other drug classes, especially the
angiotensin converting enzyme inhibitors (ACEIs) and
the angiotensin II receptor blockers (ARBs). This last
element is further illustrated by the quotations below.
“Even if you lower a patient’s blood pressure with a
diuretic, that doesn’t mean that this drug will save
his or her life later. It does not prevent infarction or
what-have-you... We’r en o tj u s tt r y i n gt ol o w e rt h e
numbers; we want to stop the pathology and morbid-
ity associated with hypertension.” (MD 13)
“Diuretics may lower the blood pressure, but they
don’t necessarily have this protective effect on target
organs that the other drug classes have” (MD 16).
Preferred approach to hypertension management
The physicians also had divergent opinions regarding
what constitutes the “best approach to hypertension
management.” Physicians who predominantly prescribe
diuretics described themselves as having a more gradual
or weighted approach for managing patients with mild
to moderate hypertension. They usually initiate antihy-
pertensive treatments gradually. For example, they will
f i r s ts t a r tt h ep a t i e n to nal o wd o s eo fad i u r e t i c ,a n d
gradually increase the dose as needed. Then, if the
hypertension is not brought under control, they will add
a low dose of a second drug class, and then optimize
t h ed o s eo ft h i sd r u gb a s e do nt h ep a t i e n t ’s response.
This approach is meant to avoid the side effects that
could potentially result from increasing the first drug to
its maximum dose:
“I usually increase the dose first, until they’re at sort
of a middling dose, like not the maximum, but the
middle dose, and then, if that doesn’tw o r ko u t ,I ’ll
add a new one... because it s been shown that it’s
more efficient to add a second medication rather
than increasing the dose.” (MD 28)
“To reach my targets, I prefer to add small doses of
other molecules instead of increasing the dosage of a
single drug to its maximum. This is to avoid the pro-
blems of side effects....” (MD 17)
In addition, physicians who predominantly prescribe
diuretics are more cautious about using new drugs with
their patients as soon as these products come out on
the market. They tend to wait for the evidence about
the effectiveness of the new products to accumulate
before inserting these drugs into their practice:
“I haven’t used Aliskiren [one of the newest antihy-
pertensive] because at the conference I went to at the
University of X, they told us it is far too new to know
the long-term effects.” (MD 7)
In comparison, physicians who predominantly pre-
scribe drug classes other than diuretics as first-line
treatment for mild to moderate hypertension are charac-
terized by a more aggressive approach to treating hyper-
tension. These physicians are notably motivated by a
desire to achieve their treatment targets rapidly. They
prefer to initiate an antihypertensive therapy with a
drug class that they believe is more potent than diure-
tics, and in most cases this will be an angiotensin con-
verting enzyme inhibitor (ACEI) or angiotensin II
receptor blocker (ARB). The following quotations sum-
marize this perspective:
“I generally follow the guidelines but not for always
starting with diuretics alone; for me, at this point, it
s not enough, and I don’t want to waste my time.”
(MD 3)
“Maybe I’m wrong, but I don’t think that a diuretic
alone can decrease the blood pressure quite signifi-
cantly. For this reason, I always start with a drug
that I know will quickly and significantly decrease
the blood pressure.” (MD 5)
“It’s not typical of my practice to prescribe diuretics
alone. It’s possible that they are effective in very mild
hypertension but generally, for moderate hyperten-
sion, diuretics alone won t work. This is why I
usually start with an ARB, very often in combination
with a diuretic.” (MD 16)
“For moderate hypertension, that is when the patient
has a diastolic pressure of about 150 mmHg, then, I
know that a thiazide diuretic will not work. For me,
at this point, I will start with another drug class.”
(MD 20)
For these reasons, these physicians usually initiate a
treatment with an ACEI or an ARB. If this treatment is
not effective, they prefer to increase the dose of the
selected antihypertensive to the maximum tolerated by
the patient before adding another drug. This is because
they believe that: 1) drug combinations are associated
with greater chances of experiencing adverse effects; 2)
taking more than one medication for hypertension is
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treatment. As such, whenever they need to prescribe
more than one antihypertensive drug to a patient, they
will usually prefer the combination products (e.g. an
ARB or an ACE combined with a thiazide diuretic). The
following quotations summarize these points:
“I treat hypertension aggressively... we’ve always trea-
ted hypertension aggressively. If there’sn os i d ee f f e c t ,
I tend to increase the drug until I get to a full dose
for the drug, before I add a second one.” (MD 1)
“... I think it is important to go to the maximum dose
of a given drug. Because the more you add molecules,
t h em o r ey o ui n c r e a s et h ec h a n c e so fh a v i n gs i d e
effects and drug interactions.” (MD 8)
“A lot of my patients are taking diuretics as an add-
on, usually to an ACE or an ARB. Sometimes I com-
bine a diuretic if it comes in the same pill because in
terms of compliance, if the patient takes one pill, the
compliance will be better than with two. So diuretics
for me are mainly an add-on to and ACE or an ARB
in the greatest majority of my patients... Considered
that in order to give renal protection, I prefer to give
them an ACE or an ARB first. And then to bring up
the target I would add after a while of taking and
ACE or an ARB, I would add a diuretic, usually in
combination. I would try to find a drug that has a
combination product.” (MD 9)
“Well, usually I like to increase to a reasonable
amount, so I’ll increase until there are side effects, or
to the recommended dosages, and then often for med-
ications there’s a maximum dose, but it’s not usually
effective over a dose that’s not the maximum dose. So
I’ll usually go to the “maximum effective dose”,n o t
necessarily that maximum tolerated dose. And then,
we’ll add.” (MD 25)
Finally, physicians who predominantly prescribe drug
classes other than diuretics as first-line treatment for
mild to moderate hypertension are more inclined than
physicians who predominantly use diuretics to prescribe
new drugs as soon as they are on the market. These
physicians also appear to be more influenced by the
marketing activities of pharmaceutical companies or by
their interactions with pharmaceutical representatives:
“The pharmaceutical representative brought me all
sorts of data about Aliskiren [one of the newest anti-
hypertensive], its efficacy, an excellent renal protec-
t i o n ,e t c .I ’ve used it a few times already and I’ve
found a very, very good response with no side effects;
it has a kind of power, [...] it is a very interesting
drug.” (MD 29)
“I have always said to myself ‘it’s best to take a med-
ication that does the job well and is not expensive’
but we are so ‘bombarded’ with encouragement to
always prescribe the ‘Cadillac’ drug that it’sh a r dt o
resist.” (MD 2)
“I think we are very solicited by pharmaceutical com-
panies, and that they do a good job of flogging their
product, since we may be prescribing too much high-
performance, do-it-all drugs. I didn’t remember this
[the results of the ALLHAT study regarding the effi-
cacy of diuretics].” (MD 16).
Perceptions about hypertension guidelines
Physicians from both groups agreed with evidence-based
guidelines suggesting that patients with complicated
hypertension (i.e., patients with diabetes, renal or cardiac
disease) should be started on an angiotensin converting
enzyme inhibitor (ACEI) or an angiotensin II receptor
blocker (ARB) to ensure the required cardiovascular or
renal protection. In addition, physicians from both
groups agreed with the treatment targets put forward by
these guidelines. However, physicians who predomi-
nantly prescribe drug classes other than diuretics
believed that the guidelines (or the studies underlying
them) put too much emphasis on the affordability of the
diuretics, at the expense of their adverse effects and
related compliance issues. When talking about their per-
ceptions of the hypertension guidelines, these physicians
also reiterated their doubts about the equivalent efficacy
of the diuretics for lowering blood pressure:
“I think the results of the ALLHAT study are prob-
ably right... but I don’t think this study assessed the
side effects and the compliance issues associated with
taking diuretics. It is true that diuretics are very, very
cheap. But a lot of my patients stopped taking diure-
tics after a few days of treatment because they were
constantly urinating...” (MD 4)
“My preferred first line drugs are ACEIs because I get
a better control of the blood pressure with these
drugs, and with fewer side effects. For me, diuretics
are a second line option. So, I don t agree with the
guidelines that suggest starting with diuretics, mainly
due to the side effects of these drugs.” (MD 11)
“When I use diuretics in my practice, I can observe
their effects on the patients. I can see that, despite
what the guidelines recommend and what the ALL-
HAT study says, they are not that potent. When I
introduce a diuretic alone versus when I use it in a
combination with another drug, I can see that diure-
tics alone don’t have a very strong impact on redu-
cing the blood pressure” (MD 20).
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Hypertension is a prevalent condition worldwide, and
one of the most modifiable risk factors for cardiovascu-
lar morbidity and mortality [1-5]. Despite extensive evi-
dence suggesting that thiazide diuretics are the most
cost-effective option for treating mild to moderate
uncomplicated hypertension [12-16], physicians often
opt for more expensive drugs [6,19]. This study sought
to describe the characteristics of physicians’ decision-
making process regarding hypertension treatment
choices.
We found that physicians who predominantly pre-
scribe drug classes other than diuretics believe that
diuretics are less effective than other drug classes in
reaching patients’ blood pressure targets. In addition,
these physicians believe that diuretics generally have
more side effects than more recent antihypertensive
agents, such as angiotensin II receptor blockers (ARBs)
or angiotensin converting enzyme inhibitors (ACEIs).
Lastly, they believe that diuretics offer less protection
against future morbidity and mortality. Of interest, there
is no evidence to support these perceptions in the
literature.
Indeed, systematic reviews and meta-analysis of major
hypertension trials have provided evidence that low-dose
diuretics are: a) as effective at lowering blood pressure
as newer and more expensive agents such as ACEIs and
ARBs, b) the most effective first-line treatment for pre-
venting the occurrence of future cardiovascular morbid-
ity and mortality, with results consistent across age and
sex strata and, c) equally or better tolerated than the
newer antihypertensive agents [12,16,38,39]. Despite this
evidence, misperceptions about the efficacy, safety and
tolerability of diuretics remain, and these misperceptions
have been reported as factors that contribute to physi-
cians’ unwillingness to use diuretics for the treatment of
patients with mild to moderate uncomplicated hyperten-
sion [40-42].
One potential explanation for these misperceptions is
the influence of the marketing strategies employed by
the pharmaceutical industry. We have indeed noted that
physicians who predominantly prescribe drug classes
other than diuretics appear to be more influenced by
the marketing activities of pharmaceutical companies or
by their interactions with pharmaceutical representa-
tives. This observation is consistent with a growing body
of literature suggesting that physicians’ misperceptions
about the efficacy of diuretics may result from: a) the
extensive promotion of the newer drug classes at medi-
cal meetings and in medical journals and, b) the wide-
spread overemphasis on the possible but unproven
problems resulting from using diuretics [42,43]. Efforts
to increase physicians’ prescribing of diuretics may need
to be directed at overcoming these misperceptions. In
addition, an interesting area for further investigation
would be an exploration of the reasons why physicians
who predominantly prescribe diuretics appear to be
immune to the influence of the marketing strategies
employed by the pharmaceutical industry.
We also noted that physicians who predominantly
prescribe drug classes other than diuretics prefer to use
them as an add-on to an ACEI or an ARB in the initial
phases of treatment for mild to moderate hypertension.
This would appear to be contradictory. Indeed, if these
physicians truly believe that diuretics cannot be used as
first-line therapy for the treatment of mild to moderate
hypertension due to their poorer side effects profile and
their lower effectiveness in reducing patients’ blood
pressure compared to other drugs, why is it that diure-
tics can be seen as an acceptable second-line therapy? A
similar inconsistency was also observed among a group
of general practitioners in Germany in a recent study
conducted by Kuehlein et al. [44]. It was observed that
among patients who received an antihypertensive mono-
therapy (30.6%), only 8.6% where prescribed some diure-
tics and 1.5% received hydrochlorothiazide (HCT).
However, among patients who received an antihyperten-
sive combination therapy (69.4%), 79.0% received some
diuretics, of which 80.8% had a combination with HCT
[44]. As for Kuehlein et al. [44], we could not find any
explanation as to why diuretics’ side-effects perceivable
by patients when used in monotherapy should disappear
in combination therapy.
In addition, we found that physicians who predomi-
nantly prescribe drug classes other than diuretics are
characterized by a more aggressive approach to hyper-
tension treatment and by a desire to reach their blood
pressure targets rapidly. This approach is probably desir-
able given that therapeutic inertia has been identified as
one of the most important modifiable factors that con-
tribute to poor blood pressure control [45]. Indeed, it is
estimated that for middle-aged patients with uncompli-
cated hypertension, 43% of primary care physicians
would not initiate pharmacological therapy unless systo-
lic blood pressure is greater than 160 mmHg, and 33%
would not initiate therapy unless diastolic blood pres-
sure is greater than 95 mmHg [43]. Moreover, in
patients without complications who are currently receiv-
ing an antihypertensive therapy, 33% of physicians
would not intensify therapy for a persistent systolic
blood pressure of 158 mmHg and 25% would not for a
persistent diastolic blood pressure of 94 mmHg [43]. As
such, the fact that physicians who predominantly
prescribe drug classes other than diuretics describe
themselves as being more aggressive in managing hyper-
tension, and as wanting to achieve their blood pressure
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Page 7 of 10targets rapidly, is probably desirable and suggests that
these physicians may be immune to clinical inertia.
Additional studies are required to validate this observa-
tion, and to determine if blood pressure control rates
differ between physicians who predominantly prescribe
diuretics and those who predominantly prescribe other
drug classes. While having an aggressive approach to
the management of hypertension may be desirable, the
strategy used by physicians who predominantly prescribe
drug classes other than diuretics for reaching their
blood pressure target may be questioned. Indeed, we
have noted that these physicians often prefer to increase
the dose of their initial treatment choice–which is often
an ACEI or an ARB–to the maximum tolerated by the
patient before adding a medication from another drug
class. However, studies have shown that single drug
therapy, even when maximally titrated, is at best only
modestly effective in normalizing blood pressure for
patients with mild to moderate hypertension [46].
Indeed, in most patients for which blood pressure tar-
gets are difficult to achieve the use of multidrug combi-
nations will often produce greater blood pressure
reduction at lower doses of the component agents,
resulting in fewer adverse events [47,48].
An important strength of our study was the use of the
chart stimulated recall interview approach. This method
allowed us to interview physicians about their actual
practice decisions with real hypertensive patients. This
method offers new insights over existing methods, such
as manual chart review, surveys or hypothetical case stu-
dies, as it allows physicians to reflect on their current
prescribing behaviors for patients in their practice and
to comment on the rationale for their treatment selec-
tion. In addition, with the growing availability of electro-
nic medical records, the approach used in this study
offers new and very interesting avenues for qualitative
researchers interested in studying physicians’
performance.
Our study also has several limitations. First, it was
limited to a jurisdiction where a significant proportion
of the vulnerable population is covered by a public drug
plan. Factors influencing physicians’ decisions may thus
differ in other jurisdictions where patients are paying for
their drugs. In addition, we investigated the factors
influencing physicians’ treatment choices for a single
health condition. It is possible that these factors vary by
type of health problem. Therefore, additional studies
conducted with patients in other jurisdictions and with
patients presenting a variety of health conditions are
recommended.
Conclusions
Thiazide diuretics are cost-effective for the treatment of
mild to moderate uncomplicated hypertension, but
physicians often opt for more expensive treatment
options such as angiotensin II receptor blockers (ARBs)
or angiotensin converting enzyme inhibitors (ACEIs).
This study sought to describe the characteristics of phy-
sicians’ decision-making process regarding hypertension
treatment choices. We found that physicians who predo-
minantly prescribe drug classes other than diuretics
appear to have several misperceptions regarding the effi-
cacy, the safety and the tolerability of diuretics. Our
data also indicate that the marketing strategies
employed by the pharmaceutical industry may contri-
bute to these misperceptions. Efforts to increase physi-
cians’ prescribing of diuretics may need to be directed
to overcoming misunderstandings about the effective-
ness and tolerability of these medicines.
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